CSL (ASX:CSL) (USOTC:CSLLY), an Australia-based global biotechnology company, announced on Monday that it has opened its new state-of-the-art research and development (R&D) centre in Waltham, Massachusetts.

The facility covers around 140,000 square feet area with 54,000 square feet of lab space, including the first biosafety level three laboratory (BSL-3) in Waltham. It is to serve as the company's central hub for present and future vaccine design.

Jon Edelman, SVP of the CSL Vaccines Innovation Unit, said, 'CSL's growing R&D presence in Waltham is the latest example of our investment in our future – which includes advancing our growing capabilities in disruptive technologies like next-generation mRNA. At this site, we aim to develop the vaccines that will help protect the public in the decades ahead and facilitate collaboration with local partners to drive our next wave of innovation.'